Adding Navitoclax to Ongoing Ruxolitinib Therapy in Patients With Myelofibrosis With Progression or Suboptimal Response
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
J. Clin. Oncol 2022 Feb 18;[EPub Ahead of Print], CN Harrison, JS Garcia, TCP Somervaille, JM Foran, S Verstovsek, C Jamieson, R Mesa, EK Ritchie, SK Tantravahi, P Vachhani, CL O'Connell, RS Komrokji, J Harb, JE Hutti, L Holes, AA Masud, S Nuthalapati, J Potluri, N PemmarajuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.